1. A phase 2 prospective, randomized, double-blind trial comparing the effects of tranexamic acid with ecallantide on blood loss from high-risk cardiac surgery with cardiopulmonary bypass (CONSERV-2 Trial) 
Paula M. Bokesch, MD, Gabor Szabo, MD, Ryszard Wojdyga, MD, Hilary P. Grocott, MD, FRCPC, Peter K. Smith, MD, C. David Mazer, MD, FRCPC, Santosh Vetticaden, MD, PhD, Alistair Wheeler, MD, Jerrold H. Levy, MD, FAHA 
The Journal of Thoracic and Cardiovascular Surgery 
Volume 143, Issue 5, Pages (May 2012)
DOI: /j.jtcvs
Copyright © 2012 The American Association for Thoracic Surgery Terms and Conditions

2. Figure 1 CONSORT flow diagram.
The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /j.jtcvs )
Copyright © 2012 The American Association for Thoracic Surgery Terms and Conditions

3. Figure 2
Mean cumulative volume of PRBCs transfused during surgery through hospital discharge. ∗∗∗P < .001 for comparison between treatment groups (Wilcoxon rank-sum test). CI, Confidence interval; PRBC, packed red blood cell.
The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /j.jtcvs )
Copyright © 2012 The American Association for Thoracic Surgery Terms and Conditions

4. Figure 3
The effect of tranexamic dose on transfusion of PRBC. P values based on the Wilcoxon rank-sum test. CI, Confidence interval; PRBC, packed red blood cell.
The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /j.jtcvs )
Copyright © 2012 The American Association for Thoracic Surgery Terms and Conditions